The latest meeting saw EMA’s human medicines committee (CHMP) recommend the approval of nine new medicines, refuse two biosimilar medications and recommend extensions of therapeutic indication for six medicines.
List view / Grid view
The UK regulator concluded that breast cancer patients taking tucatinib live longer, but it is unclear how long for and whether it is cost effective.
MR-guided focused ultrasound safely delivered antibody therapy to breast cancer that has metastasised to the brain in Phase I study.
Seagen's Tukysa® (tucatinib) was approved in the UK as part of a combination regimen for the treatment of adults with locally advanced or metastatic HER2-positive breast cancer.
New research has suggested that the expiration of biologics patents will be the factor that positively impacts US pharma the most this year.
A trastuzumab biosimilar has been pre-qualified by WHO, marking its first, to improve access to the breast cancer treatment.
2019 has seen a marked increase of antibody biosimilar product approvals in the first half of the year, according to a report.
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer...
A team of Iranian researchers have determined that trastuzumab taken with a heart drug leads to less heart damage in breast cancer patients...
The antibody ZW25 can bind two distinct regions of the HER2 receptor to block the growth of cancer cells and has shown signs of anti-tumour activity...
A study trialling a short course of trastuzumab in HER2 positive breast cancer patients showed that it is as effective and cheaper than a longer course...
Cardiac monitoring of high-risk breast cancer patients should be prioritised, after research revealed low rates of heart monitoring seen in the patients receiving trastuzumab.